0RIM Stock Chart & Stats
€0.08
>-€0.01(-1.42%)
At close: 4:00 PM EST
€0.08
>-€0.01(-1.42%)
Day’s Range― - ―
52-Week Range€0.08 - €0.24
Previous CloseN/A
Volume100.00
Average Volume (3M)6.45K
Market Cap
€19.15M
Enterprise Value€23.78M
Total Cash (Recent Filing)€2.42M
Total Debt (Recent Filing)€12.86M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding235,044,330
10 Day Avg. Volume3,968
30 Day Avg. Volume6,447
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€10.50M
Bulls Say, Bears Say
Bulls Say
Focused Gene-therapy PipelineGenSight's concentrated R&D focus on gene therapies for retinal neurodegeneration (e.g., LUMEVOQ for LHON) builds durable scientific specialization and regulatory pathway expertise. For orphan ophthalmology indications this can create high barriers to entry, potential pricing power and long-term revenue per approved asset.
Reduced Debt BurdenLower nominal debt to ~€12.9M improves solvency headroom versus prior years, reducing near-term interest and refinancing pressure. A smaller debt load enhances financial flexibility and extends runway, making future financings or partnership negotiations less constrained by high leverage.
Improving Cash Burn TrendOperating cash outflows narrowed materially in 2025, indicating better cost control or program prioritization. A sustained reduction in burn rate lengthens runway, lowers dependency on dilutive financing and creates clearer paths to execute clinical milestones or secure partnerships over the medium term.
Bears Say
Collapsed RevenueA near-total revenue collapse erodes commercial scale and raises structural questions about product sales or one-off revenues. With revenue visibility impaired, the company faces heightened funding needs to support R&D and clinical programs, making long-term planning and investment riskier.
Persistent Operating LossesChronic operating losses mean the business cannot self-fund development and must rely on external capital or partnerships. Over time, repeated financing rounds can dilute shareholders, constrain strategic options, and divert management focus from execution to fundraising.
Negative Shareholders' EquitySustained negative equity is a structural solvency concern that limits borrowing capacity and investor flexibility. It raises the probability of distressed financing, restructuring, or dilutive capital raises, all of which can impair long-term strategic execution and stakeholder confidence.
GenSight Biologics SA News
0RIM FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest share price was €0.08 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €19.15M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Sep 29, 2026 which is in 53 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Mar 27, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.027.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently same.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 235,044,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.299%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in GB:0RIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
0RIM Stock 12 Month Forecast
Average Price Target
€0.08
▲(0.00% Upside)